Insider Selling: Septerna (NASDAQ:SEPN) SVP Sells $114,922.98 in Stock

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 3,334 shares of Septerna stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $34.47, for a total transaction of $114,922.98. Following the transaction, the senior vice president owned 96,412 shares in the company, valued at $3,323,321.64. This represents a 3.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Septerna Price Performance

NASDAQ:SEPN opened at $38.83 on Friday. Septerna, Inc. has a one year low of $10.62 and a one year high of $40.65. The business has a fifty day moving average price of $34.40 and a 200-day moving average price of $29.00. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of -47.94 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, May 11th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.23. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%.The company had revenue of $26.52 million for the quarter, compared to the consensus estimate of $16.98 million. On average, equities research analysts expect that Septerna, Inc. will post -1.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SEPN. Woodline Partners LP lifted its position in Septerna by 94.2% during the first quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after purchasing an additional 282,585 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Septerna by 16.6% in the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock valued at $135,000 after purchasing an additional 3,323 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Septerna by 19.1% in the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock valued at $5,158,000 after purchasing an additional 78,316 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after purchasing an additional 1,315 shares during the period. Finally, CW Advisors LLC bought a new position in shares of Septerna during the 2nd quarter valued at approximately $133,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Stifel Nicolaus assumed coverage on shares of Septerna in a report on Friday, May 1st. They issued a “buy” rating and a $43.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Septerna in a report on Wednesday, July 1st. Truist Financial upped their price target on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Raymond James Financial increased their price objective on shares of Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research note on Monday, June 8th. Finally, Guggenheim lowered their target price on shares of Septerna from $52.00 to $45.00 and set a “buy” rating on the stock in a research note on Wednesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Septerna presently has an average rating of “Moderate Buy” and an average target price of $45.89.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.